Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients
| Autor: | Marisa A. Montecalvo |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty medicine.drug_class Antibiotics Opportunistic Infections Peptides Cyclic Enterococcus faecalis Microbiology Depsipeptides Neoplasms Internal medicine medicine Humans Pharmacology (medical) Gram-Positive Bacterial Infections Antibacterial agent Pharmacology Clinical Trials as Topic biology Vancomycin Resistance Ramoplanin biochemical phenomena metabolism and nutrition bacterial infections and mycoses biology.organism_classification Antimicrobial Anti-Bacterial Agents Treatment Outcome Infectious Diseases Enterococcus Vancomycin medicine.drug Enterococcus faecium |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 51:31iii-35 |
| ISSN: | 1460-2091 |
| DOI: | 10.1093/jac/dkg274 |
| Popis: | The prevention of vancomycin-resistant Enterococcus (VRE) colonization and infection continues to be a high priority for clinicians. An oral antimicrobial agent that reduces or eliminates VRE gastrointestinal colonization could be useful for preventing VRE infection in selected patients. Ramoplanin, a glycolipodepsipeptide, is the first in a new class of antimicrobials. It has excellent in vitro activity against vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. It is orally administered, and not absorbed systemically. In clinical trials, VRE gastrointestinal colonization was reduced to undetectable levels in 80-90% of patients during receipt of ramoplanin. A randomized, double-blinded, placebo-controlled multicentre study is currently being conducted to determine whether ramoplanin will prevent VRE bloodstream infection in oncology patients who are neutropenic due to treatment for a haematological malignancy or a bone marrow/stem cell transplant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|